PTC Therapeutics Inc
(STU:BH3)
€
68.8
+0.62 (+0.91%)
Market Cap: 5.70 Bil
Enterprise Value: 4.39 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 56/100 PTC Therapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 12, 2019 / 09:25PM GMT
Release Date Price:
€37.2
(-1.06%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
All right. Thanks, everybody, for joining us. I'm Marty Auster. I'm the lead SMID cap biotech analyst at Crédit Suisse, joined now by PTC Therapeutics. We have CFO, Emily Hill; CEO, Stu Peltz. Thanks for joining us. It's always the highlight of the conference to have you guys here.
You had some news, Monday. So maybe I'll give you a couple of minutes to kind of overview where PTC's at, putting 2019 review a little bit, but obviously, some really exciting news that just came out this week.
Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director
Yes. Exciting news is we have a positive result with the FIREFISH Part 2.
Emily Luisa Hill
PTC Therapeutics, Inc. - CFO & Treasurer
SUNFISH.
Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director
Sorry, SUNFISH Part 2, that was statistically significant. But
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot